Rapamycin is an FDA‐approved drug that has been in clinical use for decades for various indications, including life‐long immunosuppression to prevent organ rejection after transplantation.[34] Since rapamycin has recently also been shown to prevent diabetic complications such as retinopathy[35] and to increase insulin sensitivity in type‐1 diabetic patients,[] we believe the rapamycin‐triggered RAPID system will be particularly well suited for rapid release of insulinogenic drugs in future cell‐based diabetes therapies. The gene discussed is INS; the disease is retinal disorder.